Skip Navigation


NDT Advance Access originally published online on April 3, 2007
Nephrology Dialysis Transplantation 2007 22(8):2149-2155; doi:10.1093/ndt/gfm158
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/8/2149    most recent
gfm158v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nitescu, N.
Right arrow Articles by Guron, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nitescu, N.
Right arrow Articles by Guron, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Thrombin inhibition with melagatran does not attenuate renal ischaemia-reperfusion injury in rats

Nicoletta Nitescu1, Elisabeth Grimberg2, Sven-Erik Ricksten1, Niels Marcussen4 and Gregor Guron2,3

1Department of Anaesthesiology and Intensive Care, Institute of Clinical Sciences, 2Department of Nephrology, Institute of Medicine, 3Department of Physiology, Institute of Neurosciences and Physiology, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden and 4Department of Clinical Pathology, Odense University Hospital, Odense, Denmark

Correspondence and offprint requests to: Nicoletta Nitescu, MD, Department of Anaesthesiology and Intensive Care, Institute of Clinical Sciences, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden. Email: nicoletta.nitescu{at}vgregion.se



  Abstract

Background. Renal ischaemia-reperfusion (IR) is associated with activation of the coagulation system and inflammation within the kidney. The aim of the present study was to examine the effects of selective thrombin inhibition with melagatran on kidney morphology and function in rats subjected to renal IR.

Methods. Sprague–Dawley rats underwent renal IR (35 min of bilateral renal arterial clamping), or sham surgery. Treatment groups were: (i) IR–Saline, (ii) IR–Melagatran, (iii) Sham–Saline, and (iv) Sham–Melagatran. Twenty minutes prior to renal IR, the rats were administered a bolus dose of saline vehicle or melagatran [0.5 µmol/kg, subcutaneously (s.c.)] followed by a continuous infusion throughout (0.08 µmol/kg/h, s.c.). Forty-eight hours after IR, renal function was assessed in anaesthetized animals and kidney histology was analysed semi-quantitatively.

Results. Rats in group IR–Saline showed an approximate 85% reduction in glomerular filtration rate, 5-fold increases in fractional urinary excretion rates of sodium, potassium and water, and marked renal histological abnormalities, compared with sham (P < 0.05). Renal histopathological changes in the cortex and outer medulla were characterized by tubular necrosis and atrophy, tubular cast formation and interstitial inflammation. In addition, there was significant vascular congestion in the inner stripe of the outer medullary zone. Melagatran treatment had no significant effects on any of the abnormalities in kidney morphology or function in rats subjected to renal IR. Plasma melagatran concentrations were within a range known to exert significant antithrombotic effects, throughout the study period.

Conclusions. Thrombin inhibition with melagatran did not ameliorate abnormalities in kidney morphology or function 48 h after renal IR. These results indicate that melagatran is not renoprotective in rats subjected to renal IR.

Keywords: acute renal failure; coagulation; ischaemia-reperfusion; melagatran; thrombin; thrombin inhibitor

Received for publication: 31.10.06
Accepted in revised form: 2. 3.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.